Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis

Pathology International

Volumn 55, Issue 9, 2005, Pages 540-545

  Kim, Kyung Hee ^a   Suh, Kwang Sun ^b   Kang, Dong Wook ^a   Kang, Dae Young ^b  

^a Eulji University School of Medicine   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

BRAF; Hashimoto's thyroiditis; Papillary carcinoma; Thyroid

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; BRAF PROTEIN, HUMAN; DNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; HASHIMOTO DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PAPILLOMA; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID CARCINOMA; ADENOCARCINOMA; AUTOIMMUNE THYROIDITIS; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; POINT MUTATION; THYROID TUMOR;

ADENOCARCINOMA, PAPILLARY; ADULT; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUTATION, MISSENSE; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; THYROIDITIS, AUTOIMMUNE; TUMOR MARKERS, BIOLOGICAL;

EID: 27144475396     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2005.01866.x     Document Type: Article

References (28)

1. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: New concepts of activation. Biol Cell 2001; 93: 53-62.
2. Avruch J, Khokhlatchev A, Kyriakis JM et al. Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 2001; 56: 127-55.
3. Kolch W. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000; 351: 289-305.
4. Sithanandam G, Druck T, Cannizzaro LA, Leuzzi G, Huebner K, Rapp UR. B-raf and a B-raf pseudogene are located on 7q in man. Oncogene 1992; 7: 795-9.
5. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003; 1653: 25-40.
6. Davies H, Bignell GR, Cox C et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62: 6451-5.
7. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
8. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-57.
9. Cohen Y, Xing M, Mambo E et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95: 625-27.
10. Soares P, Trovisco V, Rocha AS et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22: 4578-80.
11. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003; 63: 4561-67.
12. Trovisco V, Vieira de Castro I, Soares P et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004; 202: 247-51.
13. Soares P, Trovisco V, Rocha AS et al. BRAF mutaions typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 2004; 444: 572-76.
14. Ott RA, Calandra DB, McCall A, Shah KH, Lawrence AM, Paloyan E. The incidence of thyroid carcinoma in patients with Hashimoto's thyroiditis and solitary cold nodules. Surgery 1985; 98: 1202-6.
15. Ott RA, McCall AR, McHenry C et al. The incidence of thyroid carcinoma in Hashimoto's thyroiditis. Am Surg 1987; 53: 442-25.
16. Wirtschafter A, Schmidt R, Rosen D et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 1997; 107: 95-100.
17. Di Pasquale M, Rothstein JL, Palazzo JP. Pathologic features of Hashimoto's-associated papillary thyroid carcinomas. Hum Pathol 2001; 32: 24-30.
18. Linger P, Ewart M, Wang BY, Gan L, Kohtz DS, Burstein DE. Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: A pathobiologic link? Hum Pathol 2003; 34: 764-9.
19. Santoro M, Carlomagno F, Hay ID et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 1992; 89: 1517-22.
20. Jhiang SM, Caruso DR, Gilmore E et al. Detection of the PTC/retTPC oncogene in human thyroid cancers. Oncogene 1992; 7: 1331-37.
21. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 2003; 88: 2745-52.
22. Nikiforova MN, Lynch RA, Biddinger PW et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003; 88: 2318-26.
23. Satta MA, Nanni S, Della Casa S, Pontecorvi A. Molecular biology of thyroid neoplasms. Rays 2000; 25: 151-61.
24. Xing M, Vasko V, Tallini G et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 2004; 89: 1365-68.
25. Nikiforova MN, Kimura ET, Gandhi M et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic plastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88: 5399-404.
26. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. BRAF mutations in anaplastic thyroid carcinoma: Implications for tumor origin, diagnosis and treatment. Mod Pathol 2004; 17: 1359-63.
27. Stephenson TJ. Papillary carcinoma of the thyroid: A tumour still with no benign neoplastic counterpart. Histopathology 2001; 39: 536-38.
28. Fink A, Tomlinson G, Freeman JL, Rosen IB, Asa SL. Occult micropapillary carcinoma associated with benign follicular thyroid disease and unrelated thyroid neoplasms. Mod Pathol 1996; 9: 816-20.